BrightSign Bolsters Reliable Media Players, Announces Unmatched 5-Year Warranty
BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will exhibit the latest in digital signage solutions at Integrated Systems Europe (ISE) 2025, booth 4S-300 in Barcelona, Spain, February 4-7. Following the momentum of a successful year for BrightSign, which saw growth across the globe, the company is doubling down on its commitment to customers and the unparalleled reliability and security of its players.
BrightSign has announced that its players are now backed by a 5-year warranty, beginning January 1, 2025. Businesses are demanding more reliable solutions with extended longevity and lower total cost of ownership, for which BrightSign digital signage solutions are renowned. This warranty commitment is a testament to the company’s confidence in the durability of BrightSign players. It presents an industry first that will change the way customers think about their hardware and what they will come to expect from their signage solutions.
“More reliable, more secure, and more value. This is the driving force behind our commitment to customers, partners, and consumers for the year ahead,” said Steve Durkee, chief executive officer of BrightSign. “The market asked, and we delivered. Expanded partnerships, more integrations, extended warranties, SOC2 compliance – all while leveraging the power of NPUs to enable AI experiences. We are incredibly confident in our full solutions suite and unmatched reliability. Digital signage is everywhere, and BrightSign is continuing to give businesses a choice in how they benefit from our media players and operating system (BrightSignOS™) to better manage, control, and display content.”
New to ISE 2025 for BrightSign:
- 5-Year Warranty, beginning January 1, 2025:*All newly purchased and registered Series 5 and beyond media players now include a standard 5-year warranty. Accompanying the fanless design, self-healing capabilities, and 5 years of software updates for its media players, BrightSign offers the most reliable solution in the market that gives customers unparalleled confidence in their signage decisions.
- AI Enablement:** BrightSign players have NPUs built into their platform, enabling partners to develop AI applications. This integration accelerates AI tasks without impacting content playback. As a result, our customers can streamline the adoption and deployment of AI capabilities across a fleet of players.
- LG Collaboration: On display for the first time, this unique collaboration shows BrightSign’s commitment to customers and partners. New LG 49-, 55-, and 65-inch UV5N-E Series models will run the trusted BrightSignOS on LG’s embedded system-on-a-chip (SoC) multi-core processor. Available to U.S. customers in the second quarter of 2025, with international markets following.
- OS Flexibility for XC5 Digital Player: For the first time at ISE, BrightSign will have its XC5 Digital Player available with BrightSignOS™ or the choice of Windows 10 IoT or Windows 11 IoT for organizations that are required to run Windows architecture.
- Bright Alliance Program: Launched in 2024, BrightSign now has 11 Elite Bright Alliance partners and 28 partners in total. 2025 will see a continued expansion into the European market, across industries including retail, QSR, higher education, healthcare, and transportation.
BrightSign will be at booth 4S-300 at ISE 2025. For more information, please visit: https://www.brightsign.biz/ise-tech-show/
About BrightSign
BrightSign LLC, the global market leader in digital signage media players, is headquartered in San Jose, California, with offices in Europe and Asia. BrightSign manufactures media players and provides free software and networking solutions for the commercial digital signage market worldwide, serving all vertical segments of the digital signage marketplace. From entry-level BrightSign LS players to BrightSign XC players offering state-of-the-art technology and unsurpassed performance, BrightSign’s products are known for their signature reliability, affordability, ease-of-use, and market-leading technology. For more information, visit BrightSign.
*Players must be registered within the first year of purchase. The warranty only applies to Series 5 and beyond players. Series 5 players purchased between November 1, 2024, and December 31, 2024, will be able to register to receive an extended 3-year warranty, bringing their total coverage to 5 years.
**Current availability on LS5, HS5, XT5.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250130524916/en/
Contacts
Paul Rechichi
brightsign@racepointglobal.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press Release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press Release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom